Research programme: MAPK1 inhibitors - VertexAlternative Names: Cancer therapeutics - Vertex Pharmaceuticals; ERK2 inhibitors - Vertex Pharmaceuticals; MAP kinase 1 inhibitors - Vertex Pharmaceuticals; Mitogen activated protein kinase 1 inhibitors - Vertex
Latest Information Update: 04 Nov 2017
Price : $50 *
At a glance
- Originator Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 23 Mar 2011 This research programme appears to be ongoing in USA
- 17 Feb 2009 This research programme is in active development in the USA.